Efficiency of Naproxen/Esomeprazole in Association for Osteoarthrosis Treatment in Spain

Capel, Margarita; Tornero, Jesús; Zamorano, José Luís; Oyagüez, Itziar; Sánchez-Covisa, Joaquín; Lanas, Ángel

doi:10.1016/j.reumae.2014.03.002

Cited by 7 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty studies included CV AEs, and 11 considered discontinuation (mostly published after 2013). Only 3 studies considered treatment adherence (55,59,60).…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis

Zhao

Ahmad

Graaff

et al. 2021

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo comprehensively synthesise the evolution of health-economic evaluation models (HEEMs) of all OA interventions including preventions, core treatments, adjunct non-pharmacological interventions, pharmacological and surgical treatments. MethodsThe literature was searched within health-economic/biomedical databases. Data extracted included: OA type, population characteristics, model setting/type/events, study perspective, comparators; and the reporting quality of the studies was assessed. The review protocol was registered at the International Prospective Register of Systematic Reviews (registration: CRD42018092937). ResultsEighty-eight studies were included. Pharmacological and surgical interventions were the focus in 51% and 44% studies, respectively. Twenty-four studies adopted a societal perspective (with increasing popularity after 2013), however most (63%) did not include indirect costs. Qualityadjusted life years (QALYs) was the most popular outcome measure since 2008. Markov models were used by 62% of studies, with increasing popularity since 2008. Until 2010, most studies used short-to-medium time horizons; subsequently a lifetime horizon became popular. Eighty-six percent of studies reported discount rate(s) (predominantly between 3% and 5%).Studies published after 2002 had a better coverage of OA-related adverse events (AEs).Reporting quality significantly improved after 2001. Conclusions 3OA HEEMs have evolved and improved substantially over time, with focus shifting from shortto-medium-term pharmacological decision-tree models to surgical-focused lifetime Markov models. Indirect costs of OA are frequently not considered, despite using a societal perspective.There was lack of reporting sensitivity of model outcome to input parameters including discount rate, OA definition, and population parameters. Whilst the coverage of OA-related AEs has improved over time, it is still not comprehensive.

show abstract

“…Twenty studies included CV AEs, and 11 considered discontinuation (mostly published after 2013). Only 3 studies considered treatment adherence (55,59,60).…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis

Zhao

Ahmad

Graaff

et al. 2021

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Characteristics of the included studies are reported in Table 2. The time periods of publication were 2000-2004 (n = 6) [40][41][42][43][44][45], 2005-2009 (n = 10) [34,35,37,[46][47][48][49][50][51][52], 2010-2014 (n = 10) [53][54][55][56][57][58][59][60][61][62], and post-2015 (n = 17) [36,38,39,[63][64][65][66][67][68][69][70][71][72][73][74][75][76]. The studies were conducted in Europe (n = 15), North America (n = 19) [36, 37, 39, 42, 45, 46, 48, 51, 54-56, 59, 60, 67-72, 75], South America (n = 1) [65], and Asia (n = 7) [35,44,…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The payer perspective was typically adopted, including third-party payer, private payer, National Health Service (NHS), and Healthcare System (HCS). The majority of articles adopted NHS (n = 8) [38,43,49,50,53,57,58,74], third-party payer (n = 3) [55,56,65], or HCS perspectives (n = 7) [38,48,58,70]. A number of CEAs offered societal perspectives (n = 8) [35,37,41,44,46,54,60,69].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review

Shi

Fan

Yan

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background and objective Osteoarthritis (OA) is a highly prevalent, disabling disease requiring chronic management that is associated with an enormous individual and societal burden. This systematic review provides a global cost-effectiveness evaluation of pharmacological therapy for the management of OA. Methods Following Center for Reviews and Dissemination (CRD) guidance, a literature search strategy was undertaken using PubMed, EMBASE, Cochrane Library, Health Technology Assessment (HTA) database, and National Health Service Economic Evaluation database (NHS EED) to identify original articles containing cost-effectiveness evaluation of OA pharmacological treatment published before 4 November 2021. Risk of bias was assessed by two independent reviewers using the Joanna Briggs Institute (JBI) critical appraisal checklist for economic evaluations. The Quality of Health Economic Studies (QHES) instrument was used to assess the reporting quality of included articles. Results Database searches identified 43 cost-effectiveness analysis studies (CEAs) on pharmacological management of OA that were conducted in 18 countries and four continents, with one study containing multiple continents. A total of four classes of drugs were assessed, including non-steroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, symptomatic slowacting drugs for osteoarthritis (SYSADOAs), and intra-articular (IA) injections. The methodological approaches of these studies showed substantial heterogeneity. The incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY) were

show abstract

“…69% had a high-risk of GI and they were prescribed treatment with PPI (free). 28 There are no direct data of improvement in adherence with the use of this combination. The inclusion of a direct communication that urged a written response significantly increased correct prescription (43-61%), although without reaching adequate prescription levels (<50%).…”

Section: Adherence To Treatmentmentioning

confidence: 99%

Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs

Sostres¹,

Lanas²

2016

Medicina Clínica (English Edition)

Self Cite

View full text Add to dashboard Cite

Efficiency of Naproxen/Esomeprazole in Association for Osteoarthrosis Treatment in Spain

Cited by 7 publications

References 26 publications

Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis

Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis

Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review

Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs

Contact Info

Product

Resources

About